SRR1394343
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.427
- KRAS_SIGNALING_DN+0.382
- IL6_JAK_STAT3_SIGNALING+0.367
- INFLAMMATORY_RESPONSE+0.363
- ALLOGRAFT_REJECTION+0.349
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.343
- COAGULATION+0.329
- ANGIOGENESIS+0.219
- COMPLEMENT+0.218
- KRAS_SIGNALING_UP+0.207
Top 10 suppressed
- PROTEIN_SECRETION-0.576
- OXIDATIVE_PHOSPHORYLATION-0.560
- MYC_TARGETS_V2-0.540
- MYC_TARGETS_V1-0.522
- DNA_REPAIR-0.499
- UNFOLDED_PROTEIN_RESPONSE-0.479
- MITOTIC_SPINDLE-0.465
- G2M_CHECKPOINT-0.369
- ADIPOGENESIS-0.368
- MTORC1_SIGNALING-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1317494 | GTEX | — | 0.953 |
| 2 | SRR1476614 | GTEX | — | 0.952 |
| 3 | SRR1321552 | GTEX | — | 0.952 |
| 4 | SRR1331289 | GTEX | — | 0.944 |
| 5 | SRR1354577 | GTEX | — | 0.942 |
| 6 | SRR1103048 | GTEX | — | 0.939 |
| 7 | SRR1366961 | GTEX | — | 0.939 |
| 8 | SRR1375616 | GTEX | — | 0.938 |
| 9 | SRR1331511 | GTEX | — | 0.936 |
| 10 | SRR1389348 | GTEX | — | 0.936 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.427 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.382 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.367 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.363 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.349 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.343 | Inavolisib | — uncovered |
| COAGULATION | 0.329 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.219 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.218 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.207 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.186 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.174 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.173 | Idelalisib | — uncovered |
| MYOGENESIS | 0.156 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.135 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.097 | Inavolisib | — uncovered |
| APOPTOSIS | 0.084 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.079 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.074 | Inavolisib | — uncovered |